Literature DB >> 22999780

5-Aminosalicylates and renal function monitoring in inflammatory bowel disease: a nationwide survey.

Camille Zallot1, Vincent Billioud, Luc Frimat, Patrick Faure, Laurent Peyrin-Biroulet.   

Abstract

BACKGROUND AND AIM: 5-Aminosalicylates (ASA) are widely used in inflammatory bowel disease (IBD). Nephrotoxicity has been described in some IBD patients treated with 5-ASA. Whether physicians managing these patients are monitoring renal function in daily practice is unknown. The aims of this paper were to investigate how private gastroenterologists monitor renal function and manage renal failure in IBD patients treated with oral 5-ASA therapy.
METHODS: This was a web-based cross sectional national survey which was conducted among private gastroenterologists.
RESULTS: A total of 249 practitioners completed the survey. Eighty two percent (n=205) of responders declared that they always monitor renal function. The respondents monitored twice a year Glomerular Filtration Rate (eGFR) using Modification of Diet in Renal Disease (MDRD) [90% (n=225)] and Creatinine Clearance (CCr) using a 24-hour urine collection [51% (n=126)]. Blood electrolytes, 24-hour urinary protein rate and dipsticks are performed by 41%, 39% and 22% of practitioners, respectively. Before oral 5-ASA initiation, 59% (n=148) of respondents screen for renal failure. In case of elevated serum creatinine, a nephrologist's opinion is asked by 80% (n=200) of responders and by 76% (n=189) of respondents before treatment initiation.
CONCLUSIONS: Most gastroenterologists are monitoring renal function once or twice a year in IBD patients on 5-ASA. Less than two thirds of them screen for renal failure before treatment initiation. MDRD is mainly used, but a wide range of parameters is evaluated.
Copyright © 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22999780     DOI: 10.1016/j.crohns.2012.08.013

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  4 in total

1.  Do gastroenterologists monitor their patients taking 5-amino-salicylates following initiation of treatment.

Authors:  N Siddique; C Farmer; A F Muller
Journal:  Frontline Gastroenterol       Date:  2014-06-04

2.  Inflammatory Bowel Diseases Are Associated With an Increased Risk for Chronic Kidney Disease, Which Decreases With Age.

Authors:  Ravy K Vajravelu; Lawrence Copelovitch; Mark T Osterman; Frank I Scott; Ronac Mamtani; James D Lewis; Michelle R Denburg
Journal:  Clin Gastroenterol Hepatol       Date:  2019-11-01       Impact factor: 11.382

3.  Lack of Monitoring Is Associated with Risk of Acute Kidney Events among Patients with Inflammatory Bowel Disease.

Authors:  Hamza Achit; Laurent Peyrin-Biroulet; Carole Ayav; Francis Guillemin; Luc Frimat
Journal:  J Clin Med       Date:  2022-05-24       Impact factor: 4.964

Review 4.  Five-aminosalicylic Acid: an update for the reappraisal of an old drug.

Authors:  Cristiana Perrotta; Paolo Pellegrino; Eliana Moroni; Clara De Palma; Davide Cervia; Piergiorgio Danelli; Emilio Clementi
Journal:  Gastroenterol Res Pract       Date:  2015-01-21       Impact factor: 2.260

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.